Literature DB >> 15798425

High-powered holmium-laser ablation: comparison of setting effectiveness using tissue-surrogate model.

Ramsay L Kuo1, Ryan F Paterson, Tibério M Siqueira, Samuel C Kim, James E Lingeman.   

Abstract

BACKGROUND AND
PURPOSE: The 100-W holmium laser, in conjunction with a sidefiring 550-microm fiber, can ablate prostate glands as large as 40 g to relieve lower urinary-tract symptoms. We evaluated the effect of various setting combinations on ablation efficiency using beef kidney as a tissue-surrogate model.
MATERIALS AND METHODS: Beef kidney specimens (mean weight 44.8 +/- 3.1 g) were secured in a cylinder, which was submerged in a water-filled tank through which a 27F resectoscope and 550-microm sidefiring fiber were positioned. Four energy/frequency combinations were tested, with each used to treat 10 kidney specimens. The difference between the mean pretreatment and post-treatment weights of each treatment group were compared statistically with Student's t-test.
RESULTS: The largest mean weight difference after treatment (8.94 +/- 2.38 g) was achieved using 3.2 J and 25 Hz. This mass reduction was significantly greater than that of all other combinations except 2.5 J and 40 Hz.
CONCLUSIONS: Use of the 3.2 J and 25 Hz setting combination resulted in the greatest amount of ablation in this tissue-surrogate model, suggesting that maximal energy settings may provide an advantage in tissue vaporization using the 100-W holmium laser. Clinical assessment must be performed to substantiate these findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798425     DOI: 10.1089/end.2005.19.239

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  2 in total

1.  Comparison of laser fiber degradation and perioperative outcomes following holmium laser enucleation of the prostate using 550 and 1000 µm fiber diameters.

Authors:  Charles U Nottingham; Tim Large; Joshua Heiman; Chanel A Stephens; Amy E Krambeck
Journal:  Int Urol Nephrol       Date:  2019-12-20       Impact factor: 2.370

Review 2.  [Benign prostatic hyperplasia (BPH) : Surgical therapy options].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; S Walther; C Stief
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.